Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Molecular Research on Rare Thoracic Tumors
share announcement

Molecular Research on Rare Thoracic Tumors

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 7443

Special Issue Editors

Dr. Giovannella Palmieri

E-Mail Website
Guest Editor
Rare Tumors Coordinating Center of Campania Region (CRCTR), Universita degli Studi di Napoli Federico II, Naples, Italy
Interests: thymic epithelial tumors
Dr. Mirella Marino

E-Mail Website
Guest Editor
Department of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy
Interests: thymic epithelial tumors

Special Issue Information

Dear Colleagues,

Rare thoracic tumors include epithelial tumors of the trachea, rare epithelial tumors of the lung, epithelial tumors of the thymus, mesothelioma of pleura and pericardium, mediastinal germ cell tumors, neuroendocrine tumors of the thymus and lung, lymphoma of the mediastinum, and sarcoma of the thoracic cavity. These malignancies present an intrinsic complexity in the initial diagnostic phase, as well as in treatment choice, often due to unavailability of practice guidelines and the lack of data, which significantly limit treatment options.

The systematic evaluation and definition of complex and uncommon thoracic tumors requires multidisciplinary team discussion in order to reach the correct diagnosis and offer the best treatment;

therefore, the aim of this Special Issue is to collate significant recent results surrounding rare thoracic tumors.

Dr. Giovannella Palmieri
Dr. Mirella Marino
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epithelial tumors of the trachea
  • rare epithelial tumors of the lung
  • epithelial tumors of the thymus
  • mesothelioma of pleura and pericardium
  • mediastinal germ cell tumors
  • neuroendocrine tumors of the thymus and lung
  • lymphoma of the mediastinum
  • sarcoma of the thoracic cavity

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

27 pages, 2561 KiB  
Review
Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype
by Aldo Caltavituro, Roberto Buonaiuto, Erica Pietroluongo, Rocco Morra, Fabio Salomone, Pietro De Placido, Martina Pagliuca, Angelo Vaia, Margaret Ottaviano, Marianna Tortora, Sabino De Placido, Giovannella Palmieri and Mario Giuliano
Biomedicines 2023, 11(3), 874; https://doi.org/10.3390/biomedicines11030874 - 13 Mar 2023
Cited by 1 | Viewed by 2026
Abstract
Sarcomas of the thoracic cavity are rare entities that predominantly affect children and young adults. They can be very heterogeneous encompassing several different histological entities. Ewing Sarcoma (ES) can potentially arise from every bone, soft tissue, or visceral site in the body. However, [...] Read more.
Sarcomas of the thoracic cavity are rare entities that predominantly affect children and young adults. They can be very heterogeneous encompassing several different histological entities. Ewing Sarcoma (ES) can potentially arise from every bone, soft tissue, or visceral site in the body. However, it represents an extremely rare finding when it affects the thoracic cavity. It represents the second most frequent type of thoracic sarcoma, after chondrosarcoma. ES arises more frequently in sites that differ from the thoracic cavity, but it displays the same biological features and behavior of extra-thoracic ones. Current management of ES often requires a multidisciplinary treatment approach including surgery, radiotherapy, and systemic therapy, as it can guarantee local and distant disease control, at least transiently, although the long-term outcome remains poor. Unfortunately, due to the paucity of clinical trials purposely designed for this rare malignancy, there are no optimal strategies that can be used for disease recurrence. As a result of its complex biological features, ES might be suitable for emerging biology-based therapeutic strategies. However, a deeper understanding of the molecular mechanisms driving tumor growth and treatment resistance, including those related to oncogenic pathways, epigenetic landscape, and immune microenvironment, is necessary in order to develop new valid therapeutic opportunities. Here, we provide an overview of the most recent therapeutic advances for ES in both the preclinical and clinical settings. We performed a review of the current available literature and of the ongoing clinical trials focusing on new treatment strategies, after failure of conventional multimodal treatments. Full article
(This article belongs to the Special Issue Molecular Research on Rare Thoracic Tumors)
►▼ Show Figures

Graphical abstract

13 pages, 608 KiB  
Review
Primary Mediastinal Germ Cell Tumors: A Thorough Literature Review
by Guliz Ozgun and Lucia Nappi
Biomedicines 2023, 11(2), 487; https://doi.org/10.3390/biomedicines11020487 - 8 Feb 2023
Cited by 5 | Viewed by 5042
Abstract
Primary mediastinal germ cell tumors (PMGCTs) are a rare type of cancer affecting young adults. They have different molecular and clinical features compared to testicular germ cell tumors. Non-seminoma PMGCTs have the shortest 5-year overall survival and the poorest prognosis among all of [...] Read more.
Primary mediastinal germ cell tumors (PMGCTs) are a rare type of cancer affecting young adults. They have different molecular and clinical features compared to testicular germ cell tumors. Non-seminoma PMGCTs have the shortest 5-year overall survival and the poorest prognosis among all of the germ cell tumor presentations, while seminomas share the same survival and prognosis as their testicular counterparts. There is an unmet need for better treatment options for patients with non-seminoma PMGCTs in both first-line and salvage therapy, as the available options are associated with underwhelming outcomes. Identifying biological and genetic factors to predict treatment responses would be helpful in improving the survival of these patients. Full article
(This article belongs to the Special Issue Molecular Research on Rare Thoracic Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop